Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...
Guidepoint Qsight, a leader in leveraging proprietary data to provide unmatched analytics solutions, today revealed new ...
Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...
Financial writer recommends buying LifeVantage stock after exceeding Q2/FY2025 expectations with new MindBody GLP-1 System launch.
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...
GP leaders across the country are advising practices to push back on private providers requesting input for weight-loss jab ...
As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...
In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection ...
"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...
This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...
A top NYC weight-loss doctor shared the surprising skin complication that he’s encountered in patients using GLP-1 drugs like ...
Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback